Ivan Kairatov brings a wealth of experience in the biopharma sector, specifically in navigating the high-stakes world of oncology research and development. As an expert in antibody-drug conjugates, he has spent years analyzing how innovative therapies transition from the laboratory to the bedside, often under intense regulatory scrutiny. In this discussion, we explore the precarious balancing act between clinical efficacy and patient safety within the context of recent Phase 3 data for Zynlonta. We delve into the clinical implications of modest survival gains when weighed against significant safety concerns, the impact of trial design on reported outcomes, and the uncertain regulatory horizon for a drug that once seemed destined for a straightforward path to full approval.
The interview explores the tension between statistical success and real-world safety risks, the nuances of treating an aging patient population with aggressive blood cancers, and the potential fallout for a company whose entire portfolio hinges on a single asset.
Large B-cell lymphoma treatments often prioritize progression-free survival, yet a 1.4-month gain for Zynlonta seems to have sparked more concern than celebration. How do you interpret the clinical value of this result when weighed against the safety data?
The math behind this trial is a classic example of why oncology research is so grueling for everyone involved. While extending progression-free survival to 6.1 months compared to the 4.7 months seen in the standard immunotherapy arm is a statistically significant win, that 1.4-month delta feels incredibly thin when you look at the human cost. For the 440 participants involved, every extra week of life is a victory, but the “safety hiccup,” as some are calling it, is impossible to ignore. When a drug hits its primary goal but is overshadowed by a death imbalance—27 deaths in the Zynlonta arm versus only nine in the control group—the clinical community starts to feel a deep sense of unease. It is a heartbreaking scenario where the data suggests the drug works to keep the cancer at bay, but the overall survival benefit remains elusive, making that modest progression-free survival gain look like a very expensive trade-off.
The stock market reacted sharply with a 50% drop in share value despite the trial technically meeting its primary goal. What does this tell us about the current appetite for risk in the biopharma sector, especially regarding drugs with accelerated approval?
The market’s reaction was a visceral “no confidence” vote because investors smell regulatory blood in the water. When a company like ADC Therapeutics relies on a single asset, there is absolutely zero room for error, and a 50% wipeout reflects the fear that Zynlonta may never cross the finish line for full approval. We have to remember that this drug was granted accelerated approval back in 2021 based on a trial that didn’t even have a placebo arm for comparison. Now that we have a Phase 3 trial comparing it to a cocktail of rituximab, gemcitabine, and oxaliplatin, the flaws are being laid bare under a much harsher spotlight. For regulators and physicians, a “statistically significant” result is meaningless if they feel they are potentially shortening a patient’s life or providing a “difficult to accept” risk profile, and the market is simply pricing in the high probability that the FDA might agree.
Some analysts have pointed to the trial’s design and the age of the participants as mitigating factors for the high death rate. How much weight should we give to the fact that many of these patients were over 75 with aggressive disease?
It is a valid and nuanced point, but it doesn’t entirely clear the drug’s name. In this specific study, the researchers tracked deaths for up to 105 days after treatment, which is a much longer window than the 30-day period used in previous trials. When you are dealing with a population of patients aged 75 or older who have aggressive, hard-to-treat lymphoma, you are essentially working with the most fragile demographic in oncology. These patients often have poor overall health to begin with, and any toxicity from an intensive regimen can be the tipping point. However, even if we account for the 105-day tracking window and the advanced age of the participants, the fact remains that there were three times as many deaths in the group receiving Zynlonta. That is a heavy burden for the company to explain away when they meet with the FDA this August.
With a regulatory submission planned for the fourth quarter, the stakes couldn’t be higher for the company. What do you believe will be the deciding factor for the FDA when they review the benefit-risk profile of this combination therapy?
The FDA is going to look at the “detrimental effect”—or the lack thereof—on overall survival with a magnifying glass. ADC Therapeutics has stated there was no detrimental effect on survival, but without a clear positive trend to balance out those 27 deaths, the “modest” benefits might not be enough to justify a full approval. The agency has to decide if the 6.1 months of progression-free survival is a meaningful enough outcome for a patient who has already failed two other treatments, or if the safety risks are simply too high for the general population. It is a high-stakes poker game where the company is betting that their data on elderly patients will provide enough context to soothe regulatory nerves. The outcome of that August meeting will essentially decide whether this drug becomes a standard of care or a cautionary tale in the world of antibody-drug conjugates.
What is your forecast for Zynlonta?
I expect a very turbulent road ahead where the drug eventually secures full approval but with significant “black box” warnings or restricted usage guidelines specifically targeting the elderly population. The FDA is often hesitant to pull a drug that shows some efficacy in a “hard-to-treat” space where options are limited, but they will likely demand even more post-marketing data to ensure the death imbalance was indeed a result of trial design rather than drug toxicity. We will probably see the company forced to conduct additional sub-group analyses to prove that younger, healthier patients can handle the regimen without the same risks. Ultimately, while the regulatory path is still open, the commercial potential of the drug has likely peaked, as physicians will be extremely cautious about prescribing a treatment that carries such a heavy safety shadow.
